top of page

BackTable / Urology / Podcast / Episode #80

Active Surveillance for Prostate Cancer

with Dr. Kara Watts, Dr. Minhaj Siddiqui, and Dr. Arvin George

In this episode of BackTable Urology, Dr. Aditya Bagrodia, Dr. Kara Watts (Montefiore Medical Center), Dr. Minhaj Siddiqui (University of Maryland), and Dr. Arvin George (University of Michigan) discuss active surveillance for prostate cancer.

Be part of the conversation. Put your sponsored messaging on this episode. Learn how.

Active Surveillance for Prostate Cancer with Dr. Kara Watts, Dr. Minhaj Siddiqui, and Dr. Arvin George on the BackTable Urology Podcast)
Ep 80 Active Surveillance for Prostate Cancer with Dr. Kara Watts, Dr. Minhaj Siddiqui, and Dr. Arvin George
00:00 / 01:04

BackTable, LLC (Producer). (2023, February 15). Ep. 80 – Active Surveillance for Prostate Cancer [Audio podcast]. Retrieved from https://www.backtable.com

Free CME

Reflect on how this Podcast applies to your day-to-day and earn free AMA PRA Category 1 CMEs. Follow the button below to claim your credits on CMEfy.

BackTable CMEfy button

Stay Up To Date

Follow:

Subscribe:

Sign Up:

Podcast Contributors

Dr. Kara Watts discusses Active Surveillance for Prostate Cancer on the BackTable 80 Podcast

Dr. Kara Watts

Dr. Kara Watts is an attending urologist and associate professor with Montefiore Medical Center in New York.

Dr. Minhaj Siddiqui discusses Active Surveillance for Prostate Cancer on the BackTable 80 Podcast

Dr. Minhaj Siddiqui

Dr. Mohummad Minhaj Siddiqui is the director of urologic oncology and robotic surgery at the University of Maryland Medical System in Baltimore.

Dr. Arvin George discusses Active Surveillance for Prostate Cancer on the BackTable 80 Podcast

Dr. Arvin George

Dr. Arvin George is an associate professor of urology at the University of Michigan in Ann Arbor.

Dr. Aditya Bagrodia discusses Active Surveillance for Prostate Cancer on the BackTable 80 Podcast

Dr. Aditya Bagrodia

Dr. Aditya Bagrodia is an associate professor of urology and genitourinary oncology team leader at UC San Diego Health in California and adjunct professor of urology at UT Southwestern.

Synopsis

First, the doctors discuss workup for prostate cancer. They usually obtain an MRI prior to the diagnostic biopsy, but this decision may change in the face of inadequate infrastructure, insurance, and resources. Dr. Siddiqui notes that patients may be distressed when first hearing about their diagnosis, as prostate cancer may be the first serious illness they’ve been diagnosed with. Dr. George recommends discussing the diagnosis in person after pathology is confirmed. Additionally, Dr. Bagrodia uses the WellPrept app to send patients educational material about prostate cancer before they meet with him again.

Next, they discuss the general regimen for active surveillance patients within the first year of diagnosis. Dr. Watts orders an MRI 6 months after the diagnostic biopsy because inflammation from biopsy may be present in the first couple of months. Dr. Minhaj believes that deciding on when to do an MRI scan also depends on the patients’ preferences and personalities. They also discuss different types of biopsies and the use of confirmatory biopsies. The doctors also agree that removing the term “cancer” from grade group 1 prostate cancer could potentially minimize financial toxicity and patient anxiety. For patients who still want to pursue treatment, Dr. Bagrodia believes that urologists should have the refusal to treat patients who push for inappropriate treatment.

Finally, the doctors consider additional factors that may encourage them to consider treatment in low grade prostate cancer, such as a family history of cancer, BRCA mutations, lower urinary tract symptoms, and select molecular biomarkers and pathology characteristics. Dr. George states that the designation of high versus low volume cancer does not matter and should not be a trigger for treatment. Dr. Minhaj notes that for him, younger age is a stronger indication for active surveillance in order to avoid the morbidity of treatment.

Finally, the doctors explain their personal active surveillance regimens and tips for transitioning patients with more serious conditions off of active surveillance once their prostate cancers have been proven to be stable.

Resources

Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

backtable-earn-free-cme.jpg
backtable-plus-vi-cta.jpg
Become a BackTable Sponsor

Up Next

Enhancing Men's Health: The Role of APPs with Kenneth Mitchell, PA-C on the BackTable Urology Podcast)
Solving Semen Analysis Barriers: Innovation & Accessibility with Dr. James Smith on the BackTable Urology Podcast)
Innovating Urology: Surgeons Trailblazing Solutions with Dr. Alexandra Haessler, Dr. Jay Shakuri-Rad, and Dr. Tova Weiss on the BackTable Urology Podcast)
Empowering Clinicians through Quality Improvement Initiatives with Dr. Andrew Harris on the BackTable Urology Podcast)
Urology Advocacy: From Passion to Policy with Dr. Seth Cohen and Dr. Michelle Leach on the BackTable Urology Podcast)
Perfecting Rectal Spacer Placement for Optimal Care with Dr. Neil Taunk on the BackTable Urology Podcast)

Articles

Topics

Prostate Cancer Condition Overview
Learn about Urologic Oncology on BackTable Urology

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.

Select which show(s) you would like to subscribe to:

Thanks! Message sent.

bottom of page